We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+3.72%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$314M
AUM Growth
+$11.6M
(+3.8%)
Cap. Flow
+$13.8M
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
96.81%
Holding
15
New
1
Increased
9
Reduced
4
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$14.3M |
| 2 |
Cardinal Health
CAH
|
+$10M |
| 3 |
Exelixis
EXEL
|
+$6.08M |
| 4 |
Vanda Pharmaceuticals
VNDA
|
+$3.3M |
| 5 |
Alkermes
ALKS
|
+$352K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$17.7M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
+$2.07M |
| 3 |
Kodiak Sciences
KOD
|
+$824K |
| 4 |
United Therapeutics
UTHR
|
+$184K |
| 5 |
Assembly Biosciences
ASMB
|
+$21K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biogen
BIIB
$30B
| $49.3M | 15.7% |
184,648
+67,400
| +57% | +$14.3M |
|
|
2
United Therapeutics
UTHR
$25.8B
| $42M | 13.36% |
200,407
-821
| -0.4% | -$184K |
|
3
Regeneron Pharmaceuticals
REGN
$78.5B
| $41.9M | 13.36% |
60,889
+505
| +0.8% | +$318K |
|
|
4
Alkermes
ALKS
$8.22B
| $31.5M | 10.04% |
1,411,682
+13,523
| +1% | +$352K |
|
|
5
Enanta Pharmaceuticals
ENTA
$366M
| $30.6M | 9.73% |
589,360
-35,408
| -6% | -$2.07M |
|
6
Embecta
EMBC
$216M
| $29.5M | 9.39% |
1,024,200
+7,006
| +0.7% | +$207K |
|
|
7
Exelixis
EXEL
$13.3B
| $28.6M | 9.09% |
1,821,475
+314,590
| +21% | +$6.08M |
|
|
8
Cardinal Health
CAH
$53.9B
| $22.5M | 7.15% |
336,742
+157,903
| +88% | +$10M |
|
|
TARO
9
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $17.4M | 5.54% |
580,793
+269
| +0% | +$9.28K |
|
|
10
McKesson
MCK
$100B
| $10.8M | 3.45% |
31,913
-50,981
| -62% | -$17.7M |
|
|
11
Kodiak Sciences
KOD
$2.6B
| $3.63M | 1.16% |
469,388
-84,804
| -15% | -$824K |
|
|
EGRX
12
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $3.2M | 1.02% |
121,083
+69
| +0.1% | +$2.53K |
|
|
13
Vanda Pharmaceuticals
VNDA
$307M
| $3.09M | 0.98% |
+312,299
| New | +$3.3M |
|
14
NextCure
NXTC
$16.8M
| $86K | 0.03% |
2,608
+25
| +1% | +$1.27K |
|
|
15
Assembly Biosciences
ASMB
$498M
| – | – |
-832
| Closed | -$21K |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q3 2022 Portfolio in Review
As of Q3 2022, Krensavage Asset Management held 15 positions worth $314M, up 3.8% from $302M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Krensavage Asset Management deployed $13.8M of net new capital in Q3 2022, opening 1 new position and adding to 9 existing holdings. Its largest new stake was Vanda Pharmaceuticals: 312,299 shares worth $3.09M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was McKesson, an estimated $17.7M trimmed.
- Krensavage Asset Management's largest Q3 2022 buy was Vanda Pharmaceuticals: 312,299 shares worth $3.09M.
- Krensavage Asset Management added most to Biogen in Q3 2022, an estimated $14.3M increase.
- Krensavage Asset Management's biggest Q3 2022 reduction was McKesson, cutting an estimated $17.7M.
- Krensavage Asset Management fully exited Assembly Biosciences in Q3 2022, selling an estimated $21K.
- Krensavage Asset Management's ten largest holdings make up 97% of its $314M portfolio in Q3 2022.
- Krensavage Asset Management opened 1 new position and closed 1 in Q3 2022.
- Krensavage Asset Management's portfolio value rose 3.8% quarter-over-quarter to $314M.
Based on Krensavage Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.